Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II-III colorectal cancer.

Shin E, Lee HS, Eom DW, Kwak JY, Yang KM, Oh HS, Kim S, Yu CS

Open source

DOI
10.21037/jgo-2026-1-0024
Published
2026 Apr 30
Container
Journal of gastrointestinal oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/jgo-2026-1-0024,
  title = {Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II-III colorectal cancer.},
  author = {Shin E and Lee HS and Eom DW and Kwak JY and Yang KM and Oh HS and Kim S and Yu CS},
  year = {2026},
  journal = {Journal of gastrointestinal oncology},
  doi = {10.21037/jgo-2026-1-0024},
  url = {https://doi.org/10.21037/jgo-2026-1-0024}
}

RIS

TY  - JOUR
TI  - Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II-III colorectal cancer.
AU  - Shin E
AU  - Lee HS
AU  - Eom DW
AU  - Kwak JY
AU  - Yang KM
AU  - Oh HS
AU  - Kim S
AU  - Yu CS
PY  - 2026
JO  - Journal of gastrointestinal oncology
DO  - 10.21037/jgo-2026-1-0024
UR  - https://doi.org/10.21037/jgo-2026-1-0024
ER  - 

APA

E, S., HS, L., DW, E., JY, K., KM, Y., HS, O., S, K., & CS, Y. (2026). Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II-III colorectal cancer.. Journal of gastrointestinal oncology. https://doi.org/10.21037/jgo-2026-1-0024

Source records